Skip to main content
Scientist in a lab

Towards an HIV Cure: Industry Collaboration Group

The Towards an HIV Cure: Industry Collaboration Group was established in 2012 to bring together private sector partners, academic cure researchers and funding bodies to support collaboration in HIV cure research and development.

The Cure group facilitates and catalyses dialogue, engagement and collaboration between industry stakeholders and academic, civil society and global health institutions to accelerate scientifically promising and ethical HIV research towards remission and an HIV cure. In 2022, the Cure group joined the Corporate Partnership Programme to broaden and strengthen industry engagement in the global HIV response.

The Cure group specifically focuses on:

  • Facilitating collaboration between pharmaceutical industries and smaller biotech and diagnostics firms involved in HIV cure research and development, and enabling their engagement with academia, civil society and global health institutions
  • Supporting the design, implementation, conduct and analysis of new cure modalities
  • Addressing manufacturing and regulatory issues that may hamper the development of an HIV cure
  • Seeking and encouraging the development of initiatives to increase financial support from industry partners for HIV cure research and development

Interested in joining? Please contact [email protected].

Case studies:

Case study 1: bnAbs: From prevention to cure

At IAS 2023, the Vaccine and Cure groups co-hosted a satellite event that focused on the high potential of bnAbs in prevention and cure of HIV and explored how the research and development of bnAbs for HIV prevention can contribute to the use of bnAbs in cure strategies. The satellite examined how efforts in the prevention and cure fields can be shared to develop bnAbs that benefit both areas of research. The session drew 130 participants, generating remarkable engagement: 10,558 impressions and 297 interactions on social media.

alternative text

Case study 2: Africa HIV cure research: Strengthening industry-community engagement in clinical research

At AIDS 2022, the Cure group hosted a satellite session on how best to engage and involve communities of people living with HIV in end-to-end product development and, in particular, clinical research in Africa. Watch the satellite session here and find the report here.

alternative text

Case study 3: Monitoring HIV Viral Load during ATI 

In 2022, the group hosted a roundtable discussion that explored how best to perform point of care viral load testing in cure research involving analytical treatment interruptions (ATI) in low- and middle-income countries. To access the roundtable report, click here.  

alternative text

Case study 4: Non-invasive measurement of HIV reservoirs 

In 2022, the group hosted a workshop to discuss innovative non-invasive technology for the measurement of HIV reservoirs in low- and middle-income countries. To access the workshop report, click here

alternative text

Case study 5: Linking community to strategy

In 2021, the Cure group hosted a satellite at IAS 2021, titled “IAS Industry Cure Collaboration Group: Linking community to strategy”. Members discussed cure strategies – where are we and what is in the pipeline – and identified how to engage communities in the next phases of HIV cure clinical studies.

alternative text

Meet the Cure group members

Co-chairs

Bonnie Howell
Bonnie Howell

Bonnie Howell

Merck & Co., Inc
United States
View
Timothy Henrich
Timothy Henrich

Timothy Henrich

University of California, San Francisco
United States
View

Civil Society members

Haruna Aaron Sunday
Haruna Aaron Sunday

Haruna Aaron Sunday

Executive Director, African Network of Adolescents and Young Persons Development (ANAYDN)
Nigeria
View
Maurine Murenga
Maurine Murenga

Maurine Murenga

Lean on Me Foundation
United States
View
Richard Jefferys
Richard Jefferys

Richard Jefferys

Treatment Action Group
United States
View
Simon Collins
Simon Collins

Simon Collins

HIV i-Base, EATG and UK-CAB
United Kingdom
View

Industry members

Bryan Cobb
Bryan Cobb

Bryan Cobb

Healthcare Delivery Innovation & Collaborations Lead, Medical Science Director, Genentech
United States
View
Carey Hwang
Carey Hwang

Carey Hwang

Vir Biotechnology, Inc
United States
View
Devi SenGupta
Devi SenGupta

Devi SenGupta

Gilead Sciences, Inc.
United States
View
Heather Madsen
Heather Madsen

Heather Madsen

ViiV Healthcare
United States
View
Jeffrey Safrit
Jeffrey Safrit

Jeffrey Safrit

ImmunityBio
United States
View
Richard Dunham
Richard Dunham

Richard Dunham

Director, HIV Cure at ViiV Healthcare
United Kingdom
View
Romas Geleziunas
Romas Geleziunas

Romas Geleziunas

Executive Director in the Virology Department, Gilead Sciences
United States
View

Non-industry members

Alan Landay
Alan Landay

Alan Landay

Rush University
United States
View
David M Margolis
David M Margolis

David M Margolis

University of North Carolina at Chapel Hill
United States
View
Deborah Persaud
Deborah Persaud

Deborah Persaud

Interim Director, Pediatric Infectious Diseases and Professor of Pediatrics, Johns Hopkins
United States
View
Guido Poli
Guido Poli

Guido Poli

San Raffaele Scientific Institute
Italy
View
Javier Martinez-Picado
Javier Martinez-Picado

Javier Martinez-Picado

IrsiCaixa AIDS Research Institute, ICREA, UVic-UCC, CIBERINFEC
Spain
View
Lynda Dee
Lynda Dee

Lynda Dee

DARE CAB/amfAR Cure Institute CAB
United States
View
Michael Busch
Michael Busch

Michael Busch

Vitalant Research Institute (VRI)
United States
View
Michael Lederman
Michael Lederman

Michael Lederman

Case Western Reserve University School of Medicine
United States
View
Robert Reinhard
Robert Reinhard

Robert Reinhard

Public/global health consultant
United States
View
Rowena Johnston
Rowena Johnston

Rowena Johnston

amfAR
United States
View
Sarah Fidler
Sarah Fidler

Sarah Fidler

Imperial College London
United Kingdom
View
Sarah Palmer
Sarah Palmer

Sarah Palmer

The Westmead Institute for Medical Research
Australia
View
Steven G Deeks
Steven G Deeks

Steven G Deeks

University of California, San Francisco
United States
View
Thumbi Ndung’u
Thumbi Ndung’u

Thumbi Ndung’u

Africa Health Research Institute
South Africa
View
Yves Lévy
Yves Lévy

Yves Lévy

French National Institute for Health and Medical Research
France
View

Ex officio – International AIDS Society

Carole Beilleau
Carole Beilleau

Carole Beilleau

Director, Development and Partnerships
International AIDS Society
View
Jesse Giavina
Jesse Giavina

Jesse Giavina

Associate Officer, Resource Mobilization and Development
International AIDS Society
View
Julieta Firmat
Julieta Firmat

Julieta Firmat

Associate Officer, HIV Programmes & Advocacy
International AIDS Society
View
Nelli Barrière
Nelli Barrière

Nelli Barrière

Project Manager, HIV Programmes & Advocacy
International AIDS Society
View
Sharon Lewin
Sharon Lewin

Sharon Lewin

President
Doherty Institute for Infection and Immunity, University of Melbourne
Australia
View